The changing face of dietary therapy for epilepsy

Ludovica Pasca, Valentina de Giorgis, Joyce Ann Macasaet, Claudia Trentani, Anna Tagliabue, Pierangelo Veggiotti

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Ketogenic diet is an established and effective non-pharmacologic treatment for drug-resistant epilepsy. Ketogenic diet represents the treatment of choice for GLUT-1 deficiency syndrome and pyruvate dehydrogenase complex deficiency. Infantile spasms, Dravet syndrome and myoclonic-astatic epilepsy are epilepsy syndromes for which ketogenic diet should be considered early in the therapeutic pathway. Recently, clinical indications for ketogenic diet have been increasing, as there is emerging evidence regarding safety and effectiveness. Specifically, ketogenic diet response has been investigated in refractory status epilepticus and encephalopathy with status epilepticus during sleep. New targets in neuropharmacology, such as mitochondrial permeability transition, are being studied and might lead to using it effectively in other neurological diseases. But, inefficient connectivity and impaired ketogenic diet proposal limit ideal availability of this therapeutic option. Ketogenic diet in Italy is not yet considered as standard of care, not even as a therapeutic option for many child neurologists and epileptologists. Conclusions: The aim of this review is to revisit ketogenic diet effectiveness and safety in order to highlight its importance in drug-resistant epilepsy and other neurological disorders.(Table presented.)

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalEuropean Journal of Pediatrics
DOIs
Publication statusAccepted/In press - Sep 1 2016

Fingerprint

Ketogenic Diet
Epilepsy
Myoclonic Epilepsy
Status Epilepticus
Therapeutics
Pyruvate Dehydrogenase Complex Deficiency Disease
Neuropharmacology
Safety
Infantile Spasms
Brain Diseases
Standard of Care
Nervous System Diseases
Italy
Permeability
Sleep

Keywords

  • Dietary therapy
  • Drug-resistant epilepsy
  • GLUT1DS ketones
  • Ketogenic diet
  • Modified Atkins diet

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Pasca, L., de Giorgis, V., Macasaet, J. A., Trentani, C., Tagliabue, A., & Veggiotti, P. (Accepted/In press). The changing face of dietary therapy for epilepsy. European Journal of Pediatrics, 1-10. https://doi.org/10.1007/s00431-016-2765-z

The changing face of dietary therapy for epilepsy. / Pasca, Ludovica; de Giorgis, Valentina; Macasaet, Joyce Ann; Trentani, Claudia; Tagliabue, Anna; Veggiotti, Pierangelo.

In: European Journal of Pediatrics, 01.09.2016, p. 1-10.

Research output: Contribution to journalArticle

Pasca, L, de Giorgis, V, Macasaet, JA, Trentani, C, Tagliabue, A & Veggiotti, P 2016, 'The changing face of dietary therapy for epilepsy', European Journal of Pediatrics, pp. 1-10. https://doi.org/10.1007/s00431-016-2765-z
Pasca L, de Giorgis V, Macasaet JA, Trentani C, Tagliabue A, Veggiotti P. The changing face of dietary therapy for epilepsy. European Journal of Pediatrics. 2016 Sep 1;1-10. https://doi.org/10.1007/s00431-016-2765-z
Pasca, Ludovica ; de Giorgis, Valentina ; Macasaet, Joyce Ann ; Trentani, Claudia ; Tagliabue, Anna ; Veggiotti, Pierangelo. / The changing face of dietary therapy for epilepsy. In: European Journal of Pediatrics. 2016 ; pp. 1-10.
@article{388348a3f8624d4693b51aec24fa4be5,
title = "The changing face of dietary therapy for epilepsy",
abstract = "Ketogenic diet is an established and effective non-pharmacologic treatment for drug-resistant epilepsy. Ketogenic diet represents the treatment of choice for GLUT-1 deficiency syndrome and pyruvate dehydrogenase complex deficiency. Infantile spasms, Dravet syndrome and myoclonic-astatic epilepsy are epilepsy syndromes for which ketogenic diet should be considered early in the therapeutic pathway. Recently, clinical indications for ketogenic diet have been increasing, as there is emerging evidence regarding safety and effectiveness. Specifically, ketogenic diet response has been investigated in refractory status epilepticus and encephalopathy with status epilepticus during sleep. New targets in neuropharmacology, such as mitochondrial permeability transition, are being studied and might lead to using it effectively in other neurological diseases. But, inefficient connectivity and impaired ketogenic diet proposal limit ideal availability of this therapeutic option. Ketogenic diet in Italy is not yet considered as standard of care, not even as a therapeutic option for many child neurologists and epileptologists. Conclusions: The aim of this review is to revisit ketogenic diet effectiveness and safety in order to highlight its importance in drug-resistant epilepsy and other neurological disorders.(Table presented.)",
keywords = "Dietary therapy, Drug-resistant epilepsy, GLUT1DS ketones, Ketogenic diet, Modified Atkins diet",
author = "Ludovica Pasca and {de Giorgis}, Valentina and Macasaet, {Joyce Ann} and Claudia Trentani and Anna Tagliabue and Pierangelo Veggiotti",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s00431-016-2765-z",
language = "English",
pages = "1--10",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",

}

TY - JOUR

T1 - The changing face of dietary therapy for epilepsy

AU - Pasca, Ludovica

AU - de Giorgis, Valentina

AU - Macasaet, Joyce Ann

AU - Trentani, Claudia

AU - Tagliabue, Anna

AU - Veggiotti, Pierangelo

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Ketogenic diet is an established and effective non-pharmacologic treatment for drug-resistant epilepsy. Ketogenic diet represents the treatment of choice for GLUT-1 deficiency syndrome and pyruvate dehydrogenase complex deficiency. Infantile spasms, Dravet syndrome and myoclonic-astatic epilepsy are epilepsy syndromes for which ketogenic diet should be considered early in the therapeutic pathway. Recently, clinical indications for ketogenic diet have been increasing, as there is emerging evidence regarding safety and effectiveness. Specifically, ketogenic diet response has been investigated in refractory status epilepticus and encephalopathy with status epilepticus during sleep. New targets in neuropharmacology, such as mitochondrial permeability transition, are being studied and might lead to using it effectively in other neurological diseases. But, inefficient connectivity and impaired ketogenic diet proposal limit ideal availability of this therapeutic option. Ketogenic diet in Italy is not yet considered as standard of care, not even as a therapeutic option for many child neurologists and epileptologists. Conclusions: The aim of this review is to revisit ketogenic diet effectiveness and safety in order to highlight its importance in drug-resistant epilepsy and other neurological disorders.(Table presented.)

AB - Ketogenic diet is an established and effective non-pharmacologic treatment for drug-resistant epilepsy. Ketogenic diet represents the treatment of choice for GLUT-1 deficiency syndrome and pyruvate dehydrogenase complex deficiency. Infantile spasms, Dravet syndrome and myoclonic-astatic epilepsy are epilepsy syndromes for which ketogenic diet should be considered early in the therapeutic pathway. Recently, clinical indications for ketogenic diet have been increasing, as there is emerging evidence regarding safety and effectiveness. Specifically, ketogenic diet response has been investigated in refractory status epilepticus and encephalopathy with status epilepticus during sleep. New targets in neuropharmacology, such as mitochondrial permeability transition, are being studied and might lead to using it effectively in other neurological diseases. But, inefficient connectivity and impaired ketogenic diet proposal limit ideal availability of this therapeutic option. Ketogenic diet in Italy is not yet considered as standard of care, not even as a therapeutic option for many child neurologists and epileptologists. Conclusions: The aim of this review is to revisit ketogenic diet effectiveness and safety in order to highlight its importance in drug-resistant epilepsy and other neurological disorders.(Table presented.)

KW - Dietary therapy

KW - Drug-resistant epilepsy

KW - GLUT1DS ketones

KW - Ketogenic diet

KW - Modified Atkins diet

UR - http://www.scopus.com/inward/record.url?scp=84984856679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984856679&partnerID=8YFLogxK

U2 - 10.1007/s00431-016-2765-z

DO - 10.1007/s00431-016-2765-z

M3 - Article

SP - 1

EP - 10

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

ER -